I'm here, though I never got an answer on the status of the China FDA application yet. At this point I expect Stellar to gradually grow revenues as they partner with Distribution Companies and their products (Uracyst in particular) become more and more known by doctors/patients.
The big pay day will be if/when Watson gets Uracyst approved for the US, but that will certainly be a long term hold from here. I plan to hold and see if we don't get more recognition as our Revenues grow. Stellar certainly isn't a short-term play, but I think we'll reap the rewards in the future.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.